Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.

@article{Ko2014TamoxifenEE,
  title={Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.},
  author={Jen-Chung Ko and Hsien-Chun Chiu and Jhan-Jhang Syu and Yi-Jun Jian and Chien-Yu Chen and Yun-Ting Jian and Yi-Jhen Huang and Ting-Yu Wo and Yun-Wei Lin},
  journal={Biochemical pharmacology},
  year={2014},
  volume={88 1},
  pages={119-27}
}
Tamoxifen is a triphenylethylene nonsteroidal estrogen receptor (ER) antagonist used worldwide as an adjuvant hormone therapeutic agent in the treatment of breast cancer. However, the molecular mechanism of tamoxifen-induced cytotoxicity in non-small cell lung cancer (NSCLC) cells has not been identified. Thymidine phosphorylase (TP) is an enzyme of the pyrimidine salvage pathway which is upregulated in cancers. In this study, tamoxifen treatment inhibited cell survival in two NSCLC cells, H520… CONTINUE READING
8 Citations
53 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

in women

  • Y Feng, J Huang, Y Ding, F Xie, X Shen
  • 2011

Similar Papers

Loading similar papers…